TrimRx's Blog

Medicare’s relationship with GLP-1 drugs is the single most important coverage question in US healthcare policy.

Medicare denials for Zepbound are frustrating because the rules changed in late 2024 and most prescribers and pharmacists haven’t caught up.

Medicare denying Wegovy is one of the most common and most fixable insurance problems in 2026.

Medicaid denials for Zepbound (tirzepatide) follow a predictable pattern, and the appeal follows a predictable counter-pattern.

Medicaid denials for Wegovy are common because anti-obesity medication coverage is optional under federal Medicaid rules.

Meal prep solves the biggest practical problem on semaglutide and tirzepatide: protein consistency.

Switching between GLP-1 drugs is something patients ask about regularly.

Mazdutide is a peptide and needs cold storage to stay stable.

Introduction Mazdutide’s side effect profile is dominated by gastrointestinal symptoms during the titration phase, with about 30% of GLORY-1 trial participants reporting nausea at…